Literature DB >> 17478846

Should patient groups accept money from drug companies? No.

Barbara Mintzes1.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17478846      PMCID： PMC1865416          DOI： 10.1136/bmj.39185.394005.AD

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

Review 1.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review.

Authors:  Joel Lexchin; Lisa A Bero; Benjamin Djulbegovic; Otavio Clark
Journal:  BMJ       Date:  2003-05-31

2.  Industry funding of patients' support groups: declaration of competing interests is rare in Italian breast cancer associations.

Authors:  Paola Mosconi
Journal:  BMJ       Date:  2003-08-09

3.  Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths.

Authors:  Shelley R Salpeter; Nicholas S Buckley; Thomas M Ormiston; Edwin E Salpeter
Journal:  Ann Intern Med       Date:  2006-06-05       Impact factor: 25.391

4.  An outcomes-based approach to decisions about drug coverage policies in British Columbia.

Authors:  Steve Morgan; Ken Bassett; Barbara Mintzes
Journal:  Psychiatr Serv       Date:  2004-11       Impact factor: 3.084

5.  Funding of patients' groups.

Authors:  Maurice Slevin
Journal:  Lancet       Date:  2006-07-15       Impact factor: 79.321

6.  Sponsorship of patients' groups by drug companies should be made transparent.

Authors:  Annette Tuffs
Journal:  BMJ       Date:  2006-12-16

7.  Corporate colonization of health activism? Irish health advocacy organizations' modes of engagement with pharmaceutical corporations.

Authors:  Orla O'Donovan
Journal:  Int J Health Serv       Date:  2007       Impact factor: 1.663

8.  Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey.

Authors:  Douglas E Ball; Klara Tisocki; Andrew Herxheimer
Journal:  BMC Public Health       Date:  2006-08-03       Impact factor: 3.295
  8 in total
  16 in total

Review 1.  Patient empowerment as a component of health system reforms: rights, benefits and vested interests.

Authors:  Cinzia Colombo; Lorenzo Moja; Marien Gonzalez-Lorenzo; Alessandro Liberati; Paola Mosconi
Journal:  Intern Emerg Med       Date:  2012-01-26       Impact factor: 3.397

2.  Cancerbackup sets record straight.

Authors:  Joanne Rule
Journal:  BMJ       Date:  2007-05-19

3.  Should medical journals carry drug advertising? No.

Authors:  Gareth Williams
Journal:  BMJ       Date:  2007-07-14

Review 4.  Moving from opacity to transparency in pharmaceutical policy.

Authors:  Irfan Dhalla; Andreas Laupacis
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

5.  Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices.

Authors:  Sheila M Rothman; Victoria H Raveis; Anne Friedman; David J Rothman
Journal:  Am J Public Health       Date:  2011-01-13       Impact factor: 9.308

6.  Assessing stakeholder opinion on relations between cancer patient groups and pharmaceutical companies in Europe.

Authors:  Susanna Leto di Priolo; Andras Fehervary; Phil Riggins; Kathy Redmond
Journal:  Patient       Date:  2012       Impact factor: 3.883

7.  Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries.

Authors:  Janneke Noordman; Liset van Dijk; Roland Friele
Journal:  BMC Health Serv Res       Date:  2010-02-22       Impact factor: 2.655

8.  Coalition Priorité Cancer and the pharmaceutical industry in Quebec: conflicts of interest in the reimbursement of expensive cancer drugs?

Authors:  David Hughes; Bryn Williams-Jones
Journal:  Healthc Policy       Date:  2013-08

9.  Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness.

Authors:  Susannah L Rose
Journal:  J Law Med Ethics       Date:  2013       Impact factor: 1.718

10.  SUPPORT Tools for evidence-informed health Policymaking (STP) 15: Engaging the public in evidence-informed policymaking.

Authors:  Andrew D Oxman; Simon Lewin; John N Lavis; Atle Fretheim
Journal:  Health Res Policy Syst       Date:  2009-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.